Memory Health, the only supplement patented for the prevention and/or treatment of neurodegenerative disease, has been proven in another independent clinical study, showing benefits in patients with mild-moderate Alzheimer’s disease. The study was led by Dr. John Nolan and Dr. Rebecca Power of Nutrition Research Centre Ireland in conjunction with researchers from the Howard Foundation, University Hospital Waterford and the Royal College of Surgeons in Ireland. The results were published in the “Journal of Alzheimer’s Disease.”

The study utilized the Memory Health supplement to test the product’s formula comprised of ω-3FAs (omega-3 fatty acids), carotenoids (lutein, meso-zeaxanthin, zeaxanthin) and vitamin E regarding the impact of these micronutrients on the natural progression of Alzheimer’s Disease in a randomized controlled trial.

Following 12 months of supplementation, the active group compared to the placebo group demonstrated statistically significant improvements in skin carotenoid measurements, blood carotenoids, ω-3FAs, and vitamin E concentrations. The active group also performed better in objective measures of Alzheimer’s Disease severity, such as memory and mood, with a statistically significant difference reported in the clinical collateral for memory. In conclusion, the researchers determined that Memory Health’s combined micronutrient dietary supplement should be considered in the overall management of Alzheimer’s Disease, given the positive outcomes demonstrated in the trial.

The study can be reviewed here.

This recent study supports numerous other studies that have been conducted on Memory Health over the past 20 years, all of which have demonstrated the supplement to improve brain health and cognitive function across the board.

GRAIL LLC and Carrum Health announced a partnership to include the Galleri ® multi-cancer early detection (MCED) test as part of Carrum Health’s oncology offering to self-insured employers. This product integration will enable employers who offer Carrum Health benefits to provide eligible employees the Galleri test as part of the comprehensive cancer care Carrum delivers.

“In developing Carrum’s comprehensive oncology offering we’ve carefully selected partners who share in our mission to tackle both the rising costs of cancer care and solutions that vastly improve the patient experience,” said Sach Jain, CEO and founder of Carrum Health. “GRAIL’s early cancer detection test is a critical component in a comprehensive oncology offering and we’re thrilled to extend this benefit to Carrum members.”

Bob Ragusa, CEO at GRAIL added:

“An MCED test like Galleri complements existing screenings and represents a new approach with the potential to find cancer at earlier stages and to improve healthcare outcomes and efficiencies …We are proud to partner with Carrum Health, who shares our commitment to transforming cancer care and reducing rising healthcare costs.”

Carmine Therapeutics, a biotech startup focused on non-viral gene therapies, made the first closing of its Series A funding round. Huagai Capital led the round with another new investor, the Cystic Fibrosis Foundation, also taking part. They were joined by existing investors EVX Ventures and Simcere Pharmaceuticals.

Carmine is developing next-generation, non-viral gene therapies diseases using a proprietary Red Cell Extracellular Vesicle Gene Therapy technology platform.

To learn more, click here.

Alleva, a behavioral health tech startup, has closed a $12 million Series A round led by Ankona Capital.

The business uses its health tech platform to help clinicians to extend their reach to people with mental illness and addition. It uses a cloud-based electronic medical record and business intelligence tool to support reporting, compliance, and workflow optimization. It provides insights for evidence-based care and data-driven decisions. Its task-based dashboard aims to simplify clinician charting.

To read more, click here.

Photo: ipopba, Getty Images